Effect of sodium-glucose cotransporter type 2 inhibitors on renal outcome: An integrative review
DOI:
https://doi.org/10.33448/rsd-v12i3.40810Keywords:
Sodium-glucose transporter 2 inhibitors; Chronic kidney failure; Type 2 diabetes mellitus.Abstract
Chronic kidney disease (CKD) is characterized by progressive kidney damage with a drop in glomerular filtration rate for a period longer than three months. Among the main causes of CKD in the Brazilian population are type 2 diabetes mellitus (DM2) and systemic arterial hypertension (SAH). Drug therapy with Sodium-glucose cotransporter type 2 inhibitors (iSGLT-2) allows control of the loss of renal function and decreases the need for patients to need renal replacement therapy such as hem dialysis. Objective: To understand the effects of iSGLT-2 in reducing renal outcome, in order to know its benefits and adverse events. Methodology: This is an integrative literature review from the january 2017 to january the 2022, in the electronic databases SCIELO, PUBMED and LILACS, including work in Portuguese and English. The flow diagram was used as a tool for organizing and analyzing the articles. The works of interest were analyzed and then the results with their respective bibliographic data were organized in a frame. Results: Twelve randomized clinical trials were analyzed, of which 5 (42%) studies on canagliflozin, 4 (33%) studies on dapagliflozin, 2 (17%) on empagliflozin and only 1 (8%) study on ertugliflozin. Conclusion: SGLT-2 inhibitors are a new class of drugs that have been shown in several studies to reduce unfavorable renal outcomes, with few side effects, proving to be an important therapeutic tool in the treatment of the population of patients with renal disease.
References
Amaral, T. L. M. et al (2021). Doença renal crônica em adultos de Rio Branco, Acre: inquérito de base populacional. Ciência & Saúde Coletiva. 26(1), 339–350.
Bertoluci, M., Salles, J., Moreira, R., Pedrosa, H., Carvalho, D., Valente, F., Silva-Nunes, J., Moura, F., Hohl, A., Trujilho, F., Valerio, C., Príncipe, R., & Trujillo, T. (2020). Diretriz luso brasileira. Diabetology and Metabolic Syndrome. https://doi.org/10.1186/s13098-020-00551-1
Capellari, C., & Figueiredo, A. E. P. L. (2020). Conhecimento e Atitude: Perfil de pessoas com diabetes em diálise [Knowledge and attitude: profile of diabetics in dialysis] [Conocimiento y actitud: perfil de personas con diabetes en diálisis]. Revista Enfermagem UERJ, 28(0), 45261. https://doi.org/10.12957/reuerj.2020.45261
Cintra, R., Moura, F. A., Carvalho, L. S. F. de, Barreto, J., Tambascia, M., Pecoits-Filho, R., & Sposito, A. C. (2019). Inhibition of the sodium-glucose co-transporter 2 in the elderly: Clinical and mechanistic insights into safety and efficacy. Revista Da Associação Médica Brasileira, 65(1), 70–86. https://doi.org/10.1590/1806-9282.65.1.70
Dagogo-Jack, S., Pratley, R. E., Cherney, D. Z. I., McGuire, D. K., Cosentino, F., Shih, W. J., Liu, J., Frederich, R., Mancuso, J. P., Raji, A., & Gantz, I. (2021). Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: An analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Research & Care, 9(1), e002484. https://doi.org/10.1136/bmjdrc-2021-002484
Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018). Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes, Obesity & Metabolism, 20(8), 1988–1993. https://doi.org/10.1111/dom.13301
Ferreira, B. E., Batista, L. C. B., Silva, D. A. V. da, & Ramalho, A. da C. A. (2021). Comorbidades associadas à doença renal crônica em adultos submetidos a hemodiálise. Gep News, 5(1), 135–138.
Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., & Sartipy, P. (2018). Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, Obesity & Metabolism, 20(11), 2532–2540. https://doi.org/10.1111/dom.13413
Gonzalez, D. E., Foresto, R. D., & Ribeiro, A. B. (2020). SGLT-2 inhibitors in diabetes: A focus on renoprotection. Revista Da Associação Médica Brasileira, 66(1), 17–24. doi:10.1590/1806-9282.66
International Diabetes Federation. IDF (2021). Diabetes Atlas. Brazil, diabetes report 2000-2045. https://diabetesatlas.org/data/en/country/27/br.html
Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., Inzucchi, S. E., Wanner, C., & Koitka-Weber, A. (2021). Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 99(3), 750–762. https://doi.org/10.1016/j.kint.2020.10.031
Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Capuano, G., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Sun, T., Wheeler, D. C., Yavin, Y., … Perkovic, V. (2019). Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 140(9), 739–750. https://doi.org/10.1161/CIRCULATIONAHA.119.042007
Ministério da Saúde (2020). Relatório de Recomendação: Protocolo clínico e Diretrizes Terapêuticas do Diabete Melito Tipo 2. 565. ed. Brasília-DF: [s. n.], 2020. 131 p. http://conitec.gov.br/images/Consultas/Relatorios/2020/20201113_Relatorio_PCDT_565_Diabete_Melito_Tipo_2.pdf.
Ministério da Saúde (2020). Portaria nº 16, de 29 de abril de 2020. Torna pública a decisão de incorporar a dapagliflozina para o tratamento de diabetes mellitus tipo 2 e de não incorporar a empagliflozina para o tratamento de diabetes mellitus tipo 2, no âmbito do Sistema Único de Saúde - SUS. Disponível em < https://www.in.gov.br/en/web/dou/-/portaria-n-16-de-29-de-abril-de-2020-254919928> Acesso em 31 ago 2022.
Mozawa, K., Kubota, Y., Hoshika, Y., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., Tsukada, Y., Asai, K., Miyamoto, M., Miyauchi, Y., Kodani, E., Maruyama, M., Tanabe, J., & Shimizu, W. (2021). Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus. ESC Heart Failure, 8(5), 4161–4173. https://doi.org/10.1002/ehf2.13509
Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Lim, S. K., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., Wheeler, D. C., Zhang, H., Zinman, B., Perkovic, V., & Heerspink, H. J. L. (2021). Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 99(4), 999–1009. https://doi.org/10.1016/j.kint.2020.10.042
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, n71. https://doi.org/10.1136/bmj.n71.
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., … Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380(24), 2295–2306. https://doi.org/10.1056/NEJMoa1811744.
Sales, P., Halpern, A., Cercato, C (2016). O essencial em endocrinologia. 1. Ed. Rio de Janeiro: Roca.
Sarafidis, P., Loutradis, C., Ferro, C. J., & Ortiz, A. (2020). SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication? American Journal of Nephrology, 51(7), 553–556. doi.org/10.1159/000509082
Scott, R., Morgan, J., Zimmer, Z., Lam, R. L. H., O’Neill, E. A., Kaufman, K. D., Engel, S. S., & Raji, A. (2018). A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study. Diabetes, Obesity & Metabolism, 20(12), 2876–2884. https://doi.org/10.1111/dom.13473
Silva, D. G. da, Rodrigues, B. F. B., Brito, J. da S., Afonso, D. M., & Amato, A. A. (2015). Inibidores do cotransportador de sódio e glicose do tipo 2: efeitos além da glicosúria. Brasília Médica, 52(3–4). https://doi.org/10.5935/2236-5117.2015v52n3/4a05
Sociedade Brasileira de Diabetes (2019). Tratamento combinado: drogas orais e insulina no diabetes mellitus tipo 2. In: Diretriz da Sociedade Brasileira de Diabetes 2019-2022. [S. l.: s. n.]. http://www.saude.ba.gov.br/wp-content/uploads/2020/02/Diretrizes-Sociedade-Brasileira-de-Diabetes-2019-2020.pdf
Sociedade Brasileira de Nefrologia. (2022). Saúde dos rins para todos: educando sobre a doença renal: Preenchendo a lacuna de conhecimento para o melhor cuidado renal. In: Preenchendo a lacuna de conhecimento para o melhor cuidado renal. Online. [S. l.]. https://www.sbn.org.br/dia-mundial-do-rim/dia-mundial-do-rim-2022/
Souza, C. P., Valentim, M. C. P., Ferreira, A. D., Abdalla, P. P., Silva, L. S. L. da, Carvalho, A. dos S., & Júnior, J. R. G. (2020). Prevalência de doenças crônicas não transmissíveis, hábitos alimentares e de atividade física numa estratégia de saúde da família de Presidente Prudente – SP. ConScientiae Saúde, 19(1), 18221. https://doi.org/10.5585/conssaude.v19n1.18221
Souza, M. T. de, Silva, M. D. da, & Carvalho, R. de. (2010). Integrative review: What is it? How to do it?, Einstein (São Paulo), 8(1), 102–106. https://doi.org/10.1590/s1679-45082010rw1134
Takashima, H., Yoshida, Y., Nagura, C., Furukawa, T., Tei, R., Maruyama, T., Maruyama, N., & Abe, M. (2018). Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Diabetes and Vascular Disease Research, 15(5), 469–472. https://doi.org/10.1177/1479164118782872
Wada, T., Mori‐Anai, K., Kawaguchi, Y., Katsumata, H., Tsuda, H., Iida, M., Arakawa, K., & Jardine, M. J. (2022). Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial. Journal of Diabetes Investigation, 13(1), 54–64. https://doi.org/10.1111/jdi.13624
Wheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Umanath, K., Langkilde, A. M., & Heerspink, H. J. L. (2021). A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 100(1), 215–224. https://doi.org/10.1016/j.kint.2021.03.033
Word Kidney Disease Day. (2022). Chronic Kidney Disease: Kidney Diseases are Common, Harmful and often Treatable. In: Chronic Kidney Disease. https://www.worldkidneyday.org/facts/chronic-kidney-disease/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Cristiene Neta de Sá Araújo; Letícia Macêdo de Oliveira; Yasmim Campos Rodrigues; Luciane de Jesus Mendes Santos; Rafaella Lopes Ferreira; Willyanna Ravanielly Oliveira de Carvalho; Even Kaline Varella Jardim
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
